Propel Bio Management, LLC X4 Pharmaceuticals, Inc Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q1 2024
A detailed history of Propel Bio Management, LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Propel Bio Management, LLC holds 535,000 shares of XFOR stock, worth $438,700. This represents 0.43% of its overall portfolio holdings.
Number of Shares
535,000
Previous 535,000
-0.0%
Holding current value
$438,700
Previous $449 Million
65.77%
% of portfolio
0.43%
Previous 0.37%
Shares
1 transactions
Others Institutions Holding XFOR
# of Institutions
105Shares Held
103MCall Options Held
206KPut Options Held
291K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$13.9 Million3.55% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$12.3 Million1.46% of portfolio
-
Black Rock Inc. New York, NY8.74MShares$7.16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.83MShares$6.42 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$5.85 Million0.22% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $56.3M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...